- Home
- MLTX
as 03-14-2025 4:00pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 2.8B | IPO Year: | N/A |
| Target Price: | $83.20 | AVG Volume (30 days): | 336.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.52 - $58.26 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MoonLake Immunotherapeutics News
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
MoonLake Immunotherapeutics Q4 Loss Widens
GlobeNewswire
18 days ago
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Insider Monkey
19 days ago
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now?
Insider Monkey
21 days ago
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts
Insider Monkey
24 days ago
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now
Simply Wall St.
a month ago
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely
MT Newswires
2 months ago
Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62
TipRanks
2 months ago
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG
Compare MLTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.